Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: Focus on biallelic locus 9p21.3 deletion

Blood

Volumn 118, Issue 17, 2011, Pages 4591-4594

  Lucioni, Marco ^a   Novara, Francesca ^b   Fiandrino, Giacomo ^a   Riboni, Roberta ^a   Fanoni, Daniele ^c   Arra, Mariarosa ^a   Venegoni, Luigia ^c   Nicola, Marta ^a   Dallera, Elena ^a   Arcaini, Luca ^b   Onida, Francesco ^d   Vezzoli, Pamela ^c   Travaglino, Erica ^b   Boveri, Emanuela ^a   Zuffardi, Orsetta ^b   Paulli, Marco ^a   Berti, Emilio ^c,e  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ADULT; AGED; ALLELE; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 7P; CHROMOSOME 9P; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 80055089066     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-337501     Document Type: Article

References (25)

1. Facchetti F, Jones D, Petrella T. Blastic plasmacytoid dendritic cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:145-147.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785. (Pubitemid 40656118)
3. Petrella T, Bagot M, Willemze R, et al. Blastic NKcell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-675. (Pubitemid 40586484)
4. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
5. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74-77.
6. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm: morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
7. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
8. + DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood. 2002;99(11):4154-4159.
9. Dijkman R, Van Doorn R, Szuhai K, et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109:1720-1727. (Pubitemid 46239607)
10. Jardin F, Callanan M, Penther D, et al. Recurrent genomic aberrations combined with deletions of various tumor suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009;23:698-707.
11. Wiesner T, Obenauf AC, Cota C, et al. Alterations of the cell-cycle inhibitors p27KIP1 and p16INK4a are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol. 2010;130:1152-1157.
12. Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol. 2010;23:547-558.
13. Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2010;21(6):1189-1195.
14. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-480.
15. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leucemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMAAL WP report. J Clin Oncol. 2009;27:5202-5207.
16. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60(14):3689-3695. (Pubitemid 32204552)
17. Chu I, Hengst L, Slingerland J. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8:253-267. (Pubitemid 351430863)
18. Li Y, Pei J, Xia H, et al. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 2003;22:4398-4405. (Pubitemid 36897970)
19. Hangaishi A, Ogawa S, Imamura N, et al. Inactivation of multiple tumor suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4a/CDKN2, MTS2/p15INK4b, p53, and RB genes in primary lymphoid malignancies. Blood. 1996;87:4949-4958.
20. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol. 2006;24:3887-3894. (Pubitemid 46630736)
21. Reimer P, Rüdiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-646. (Pubitemid 37258618)
22. Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer. 2005;104:1022-1031. (Pubitemid 41170230)
23. Jardin F, Jais JF, Molina TJ, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116(7):1092-1104.
24. Senff NJ, Zoutman WH, Vermeer MH, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129:1149-1155.
25. Novara F, Beri S, Bernardo ME, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 2009;126(4):511-520.